Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

来源: 编辑: 发布: 2021-04-14 10:01

New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH.
The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvement.
The Phase 2 trials for BI 456906 in obesity and NASH are part of the long-term collaboration between Boehringer Ingelheim and Zealand Pharma, with a prior Phase 2 trial of BI 456906 in people with type 2 diabetes initiated in 2020.

INGELHEIM, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) announced the initiation of two Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH). The compound was in-licensed from Zealand in 2011 and is being investigated in an ongoing Phase 2 study in people with type 2 diabetes mellitus. The once-weekly therapy may offer additional benefits on both chronic weight management, and NASH improvement and prevention of the progression to cirrhosis compared to currently available treatments with mono GLP-1 agonist compounds. BI 456906 is part of Boehringer Ingelheim’s growing portfolio in the obesity and NASH disease areas.

“Obesity and NASH are areas of high unmet medical need, with limited approved treatments currently available. They are associated with lower quality of life and increased mortality,” explains Prof. Arun J. Sanyal, Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine in Richmond, Virginia. “I hope that this new approach will bring a much-needed treatment option for HCPs and people afflicted with obesity or NASH.”

Boehringer Ingelheim and Zealand have a fruitful longstanding partnership, bringing together Zealand’s expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases. “We are very excited to see the initiation of Phase 2 trials of BI 456906 for obesity and NASH,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. “By combining GLP-1 and glucagon agonism mechanistically, we believe our dual agonist has the potential to achieve increased weight loss, via improvement of the patient’s metabolism, and also has potential to alleviate NASH by reducing upstream steatosis.”

“Our cardiometabolic research and development is focusing on discovering novel treatments for obesity and non-alcoholic steatohepatitis (NASH), to meet the large unmet need among these groups,” explains Waheed Jamal, MD, Head of Cardiovascular, Metabolic and Respiratory Medicine at Boehringer Ingelheim. “We are exploring a number of unique approaches with great potential to help people living with obesity or NASH. We believe dual agonists are next generation drug candidates with a potential for higher efficacy in weight loss and NASH improvement/cirrhosis prevention.”

Under the terms of the GLP-1/glucagon dual agonist licensing agreement, Boehringer Ingelheim funds all research, development and commercialization activities. Zealand is entitled to receive up to EUR 345 million in outstanding milestone payments. No milestone payments are due with the initiations of these Phase 2 studies. The agreement also carries high-single digit to low-double digit percentage royalties on global sales.

Please click on the following link for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/clinical-phase2-trials-nash-and-obesity

猜你还想看:

腾讯网友:真的我爱你
评论:不怕事多,就怕多事。

搜狐网友:我们一起逃跑
评论:唐僧骑的是神马 , 悟空腾的是浮云 , 八戒爱的是小月月 , 沙僧装的是犀利哥 。

凤凰网友:离心   ■
评论:别叫我忘了你,我根本就没记住你

淘宝网友:怀念旧时光°
评论:没事的话别来找我,有事那就更别来找我了。

其它网友:- 莫失莫忘/ 
评论:快开学了,学校,你得到的我的人却得不到我的心。

网易网友:时光安好moon
评论:听说你过得不好,我坐在门口乐了一整天。

百度网友:宿命旳青春ノ
评论:人生就像愤怒的小鸟,当你失败时,总有几只猪在笑。。。

天涯网友:不懂得挽留ゝ
评论:每当我找到了成功的钥匙,就有人把锁给换了。

天猫网友:ゆ.舌尖腥咸
评论:终于知道为什么吃奥利奥会先舔一下了,因为那样就没人会和你抢了。

本网网友:- 无欲无求/ 
评论:职场三定律:要么狠 要么忍 要么滚;成功三要素:一是坚持,二是不要脸,三是坚持不要脸